Factor V Leiden and hepatic artery thrombosis after liver transplantation

Ty B Dunn, Michael A Linden, Gregory M Vercellotti, Rainer W G Gruessner

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Factor V Leiden (FVL) and other thrombophilias can be acquired during liver transplantation and can have a significant impact on clinical outcomes as well as cost. Standard practice does not include screening deceased donors for heritable thrombophilias, even if they have a personal history of thrombosis. Here we report a case of hepatic artery thrombosis in a liver recipient whose native and donor livers were heterozygous for FVL. The patient subsequently underwent a successful retransplant. FVL and its variants are expressed phenotypically as activated protein C (APC) resistance. We believe that testing liver donors (deceased or living) for APC resistance - a surrogate marker for the most common liver-based thrombophilia - will reduce the incidence of thrombotic events by identifying a need for posttransplant prophylactic anticoagulation in patients at risk. The estimated cost of testing all liver donors in the US for APC resistance is less than the cost of two complications secondary to thrombosis. Testing for APC resistance may further improve outcome and reduce cost after liver transplantation.

Original languageEnglish (US)
Pages (from-to)132-135
Number of pages4
JournalClinical Transplantation
Issue number1
StatePublished - Jan 2006


  • Cost
  • Hepatic artery
  • Prophylaxis
  • Surgical complications
  • Thrombophilia


Dive into the research topics of 'Factor V Leiden and hepatic artery thrombosis after liver transplantation'. Together they form a unique fingerprint.

Cite this